A partner for GenPrecis will not help with manufacturing of the product unless they buy it or license it from DECN. I would think that DECN is looking for sales and distribution assistance. Companies that are huge, large, medium and small should line up for GenPrecis. It is exactly what the market wants and has been looking for for the past 15 years, at-home ease of testing with near hospital laboratory accuracy and precision. The product, even if only half as good as advertised, will probably lead to an acquisition of DECN in 2020 or 2021 by its marketing and distribution partner.
And for diabetics, they will get the meters for free and pay around $.40 per strip.
(8)
(0)
Decision Diagnostics Corp (DECN) Stock Research Links